RS51110B - Alfa kristalni oblik stroncijum ranelata, postupak njegove izrade i farmaceutske smeše koje ga sadrže - Google Patents
Alfa kristalni oblik stroncijum ranelata, postupak njegove izrade i farmaceutske smeše koje ga sadržeInfo
- Publication number
- RS51110B RS51110B RSP-2008/0506A RSP20080506A RS51110B RS 51110 B RS51110 B RS 51110B RS P20080506 A RSP20080506 A RS P20080506A RS 51110 B RS51110 B RS 51110B
- Authority
- RS
- Serbia
- Prior art keywords
- expressed
- degrees
- numbers
- line
- ranelate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Steroid Compounds (AREA)
Description
Ovaj pronalazak se odnosi na kristalni oblik alfa stroncijum ranelata, postupak njegove proizvodnje, kao i na farmaceutske smeše koje ga sadrže.
Stroncijum ranelat, predstavljen formulom (I):
ili distroncijumova so 5-[bis(karboksimetil)aminc]-3-karbcksimeti!-4-cijano-2-tiofenkarboksilne kiseline, kao i njegovi hidrati, poseduje korisna farmakološka i terapeutska svojstva, između ostalog, značajne anti-osteoporozne osobine, koje ovim jedinjenjima daju upotrebljivost u lečenju i sprečavanju bolesti kostiju.
Stroncijum ranelat, kao i njegovi hidrati, ima, isto tako, svojstva koja mu daju upotrebljivost u lečenju i prevenciji artroze.
Izrada i korišćenje u terapijama stroncijum ranelata i njegovih tetrahidrata, heptahidrata i oktahidrata, opisano je u evropskom patentu EP 0415 850.
Upotreba stroncijum ranelata u prevenciji i lečenju artroze, opisana je u evropskom patentu EP 0 813 869.
Zahtevalac je sada pronašao da se stroncijum ranelat može dobiti u jednom dobro definisanom kristalnom obliku, savršeno reproduktibilnom i ovim putem ispoljava korisne karakteristike u smilslu filtracije i olakšanog formulisanja.
Preciznije, ovaj pronalazak se odnosi na alfa kristalni oblik stroncijum ranelata, kojeg karakteriše sadržaj vode od 24% i sledeći dijagram X difrakcije praška, koji je izmeren na difraktometru PANalvtical X'Pert Pro sa X'Celerator detektorom i, koji je izražen: položajem linije (Bragg 2 teta ugao, izražen u stepenima), visinom linije (izražena u brojevima) površinom linije (izražena kao brojevi x stepeni), širinom linija srednje visine ("FWHM", izraženo u stepenima) i među-mrežnom udaljenošću d (izražena u A):
Pronalazak se isto tako tiče postupka izrade alfa kristalnog oblika stroncijum ranelata, koji se karakteriše dovođenjem rastvora stroncijum ranelata ili jednog od njegovih hidrata u vodi na refluks i zatim, hlađenja dok se ne završi kristalizacija i, sakupljanja proizvoda filtracijom. • U postupku izrade, koji je u skladu sa pronalaskom, može se koristiti stroncijum ranelat ili jedan od njegovih hidrata, koji su dobijeni nekom procedurom, na primer, stroncijum ranelat oktahidrat, dobijen postupkom izrade, koji je opisan u patentu EP 0415 850. • Dobijanje ovog kristalnog oblika ima za prednost omogućavanje naročito brze i efikasne filtracije, kao i izradu farmaceutskih formulacija koje imaju jedan konstantan reproducibilan sastav, što je posebno važno kada su ove formulacije namenjene oralnoj upotrebi. • Tako dobijeni oblik je zadovoljavajuće stabilan kako bi se odobrilo njegovo produženo čuvanje bez posebnih uslova temperature, svetlosti, vlage ili kursa kiseonika.
Pronalazak se, takođe, odnosi na farmaceutske smeše koje, kao aktivan princip sadrže alfa kristalni oblik stroncijum ranelata sa jednom ili više inertnih, neotrovnih i odgovarajućih podloga. Od farmaceutskih smeša, koje su u skladu sa pronalaskom, mogu se nabrojati posebno one koje su prikladne za oralno, parenteralno (intravenozno ili subkutano), nazalno primenjivanje, jednostavne pilule ili dražeje, granule, sublingvalne pilule, želatinske kapsule, tablete, supozitorije, kremovi, masti, gelovi za kožu, injektabilni preparati, suspenzije za pijenje i paste za žvakanje.
Doziranje koje se koristi se može prilagoditi prema prirodi i ozbiljnosti bolesti, načinu primenjivanja, kao i starosti i težini pacijenta. Takvo doziranje varira od 0,2 g do 10 g dnevno u jednoj ili više doza.
Sledeći primeri ilustruju pronalazak.
Spektar X difrakcije na prašku je izmeren pod sledećim eksperimentalnim uslovima:
• PANalvtical X'Pert Pro difraktometar, X'Celerator detektor,
• Napon 45 KV, intenzitet 40 mA,
• Sklapanje 9-6,
• Filter Kp (Ni),
• Solerov prorez na umetnutoj strani i na strani difrakcije : 0,04 rad,
• prorezi razilaženja : automatski, dužina zračenja : 10 mm,
• Zaklon : 10 mm,
• Anti-difuzioni prorez : 1/2°,
• Način merenja : kontinuiran od 3° do 34° sa jednim porastom od 0,017°,
• Vreme merenja po koracima : 31,1 s,
• Ukupno vreme : 8 min 07 s,
• Brzina merenja : 0,068°/s,
• Spiner. revolucija od 1 okret/s,
• Temperatura merenja : temperatura sredine.
PRIMER1 :Alfakristalni oblik stroncijum ranelata
200 g stroncijum ranelata oktahidrata dobijeno u skladu sa postupkom opisanim u patentu EP 0415 850 je umešano u 2 1 vode i dovedeno na refluks. Sredina je onda ohlađena do 20°C.
Dobijena čvrsta materija je sakupljena filtracijom.
Sadržaj vode u dobijenom proizvodu, koji je određen gubitkom u desikatoru, je 24%, što odgovara broju molekula vode od 9 po molekulu stroncijum ranelata.
Dijagram X difrakcije na prašku:
Profil difrakcije X zraka na prašku (uglovi difrakcije) alfa oblika stroncijum ranelata je dat značajnim linijama sakupljenim u sledećoj tabeli:
PRIMER 2: Farmaceutska smeša
Formula za proizvodnju 1000 pilula doze od 0,5 g :
Claims (1)
1. Alfa kristalni oblik stroncijum ranelata formule (I):
naznačen time što je sadržaj vode 24% i sledećim dijagramom X difrakcije praška, koji je izmeren na difraktometru PANalvtical X'Pert Pro sa X'Celerator detektorom i, koji je izražen: položajem linije (Bragg 2 teta ugao, izražen u stepenima), visinom linije (izražena u brojevima) površinom linije (izražena kao brojevi x stepeni), širinom linija srednje visine ("FWHM", izraženo u stepenima) i među-mrežnom udaljenošću d (izražena u A):
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0410335A FR2875807B1 (fr) | 2004-09-30 | 2004-09-30 | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS51110B true RS51110B (sr) | 2010-10-31 |
Family
ID=34942420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP-2008/0506A RS51110B (sr) | 2004-09-30 | 2005-06-17 | Alfa kristalni oblik stroncijum ranelata, postupak njegove izrade i farmaceutske smeše koje ga sadrže |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US7459568B2 (sr) |
| EP (2) | EP1642897B9 (sr) |
| JP (2) | JP2006104184A (sr) |
| KR (1) | KR100816590B1 (sr) |
| CN (1) | CN100391956C (sr) |
| AP (1) | AP1930A (sr) |
| AR (1) | AR049395A1 (sr) |
| AT (1) | ATE411308T1 (sr) |
| AU (1) | AU2005202718B2 (sr) |
| BR (1) | BRPI0502228A (sr) |
| CA (1) | CA2508824C (sr) |
| CO (1) | CO5710195A1 (sr) |
| CR (1) | CR7876A (sr) |
| CY (1) | CY1108797T1 (sr) |
| DE (1) | DE602005010359D1 (sr) |
| DK (1) | DK1642897T3 (sr) |
| EA (1) | EA008474B1 (sr) |
| EC (1) | ECSP055859A (sr) |
| ES (1) | ES2314593T3 (sr) |
| FR (1) | FR2875807B1 (sr) |
| GE (1) | GEP20074106B (sr) |
| GT (1) | GT200500130A (sr) |
| HR (1) | HRP20080652T3 (sr) |
| IL (1) | IL169237A (sr) |
| MA (1) | MA27815A1 (sr) |
| MX (1) | MXPA05006407A (sr) |
| NO (1) | NO333948B1 (sr) |
| NZ (1) | NZ540802A (sr) |
| OA (1) | OA13013A (sr) |
| PA (1) | PA8638201A1 (sr) |
| PE (1) | PE20060364A1 (sr) |
| PL (1) | PL1642897T3 (sr) |
| PT (1) | PT1642897E (sr) |
| RS (1) | RS51110B (sr) |
| SA (1) | SA05260168B1 (sr) |
| SG (1) | SG121035A1 (sr) |
| SI (1) | SI1642897T1 (sr) |
| TW (1) | TWI367881B (sr) |
| UA (1) | UA80008C2 (sr) |
| WO (1) | WO2006035122A1 (sr) |
| ZA (1) | ZA200504937B (sr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2875807B1 (fr) * | 2004-09-30 | 2006-11-17 | Servier Lab | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| US20070292535A1 (en) * | 2006-06-19 | 2007-12-20 | Tabbiner Philip S | Strontium compositions and methods of treating arthritic and or osteoporitic conditions |
| US20070292529A1 (en) * | 2006-06-19 | 2007-12-20 | Tabbiner Philip S | Strontium compositions and methods of treating osteoporotic conditions |
| CN101206208B (zh) * | 2006-12-19 | 2011-08-10 | 北京德众万全药物技术开发有限公司 | 一种用hplc法分析雷尼酸锶原料及其制剂的方法 |
| EP2346846A1 (en) | 2008-09-29 | 2011-07-27 | Ratiopharm GmbH | Anhydrate and hydrate forms of strontium ranelate |
| IT1398542B1 (it) | 2010-03-05 | 2013-03-01 | Chemelectiva S R L | Processo per la preparazione di un polimorfo |
| CN102241663B (zh) * | 2010-05-10 | 2013-02-13 | 山东方明药业集团股份有限公司 | 一种雷奈酸锶八水合物的制备方法 |
| WO2012143932A1 (en) * | 2011-04-21 | 2012-10-26 | Shilpa Medicare Limited | Crystalline strontium ranelate form-s |
| CZ2011320A3 (cs) | 2011-05-30 | 2012-12-12 | Zentiva, K.S. | Stabilní krystalická forma X stroncium ranelátu |
| EP2530068A1 (en) | 2011-05-31 | 2012-12-05 | Lacer, S.A. | New strontium salts, synthesis and use thereof in the treatment of osteoporosis |
| WO2013013003A1 (en) | 2011-07-21 | 2013-01-24 | Emory University | Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation |
| CN102503931A (zh) * | 2011-09-20 | 2012-06-20 | 浙江华海药业股份有限公司 | 一种雷尼酸锶晶形h的制备方法 |
| WO2013113319A1 (en) * | 2012-01-31 | 2013-08-08 | Pharmathen S.A. | Process for the preparation of strontium ranelate, intermediate or hydrates thereof |
| EP2641905A1 (en) | 2012-03-23 | 2013-09-25 | Urquima S.A. | Solid forms of strontium ranelate and processes for their preparation |
| US8569514B1 (en) | 2012-05-17 | 2013-10-29 | Divi's Laboratories, Ltd. | Process for the preparation of strontium ranelate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2651497B1 (fr) * | 1989-09-01 | 1991-10-25 | Adir | Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
| ZA956029B (en) | 1994-07-22 | 1997-01-20 | Lilly Co Eli | Combination treatment for inhibiting bone loss |
| FR2749759B1 (fr) * | 1996-06-17 | 1999-11-26 | Adir | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose |
| DE19642451A1 (de) | 1996-10-15 | 1998-04-16 | Merck Patent Gmbh | Aminothiophencarbonsäureamide |
| US7227033B2 (en) * | 2002-01-09 | 2007-06-05 | Emisphere Technologies, Inc. | Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate |
| WO2003028664A2 (en) * | 2001-10-03 | 2003-04-10 | Teva Pharmaceutical Industries Ltd. | Preparation of levofloxacin and forms thereof |
| WO2004012739A1 (en) * | 2002-08-06 | 2004-02-12 | Teva Pharmaceutical Industries Ltd. | Novel crystalline forms of gatifloxacin |
| FR2844795B1 (fr) * | 2002-09-24 | 2004-10-22 | Servier Lab | Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates |
| FR2844796A1 (fr) * | 2002-09-24 | 2004-03-26 | Servier Lab | Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates |
| FR2844797B1 (fr) * | 2002-09-24 | 2004-10-22 | Servier Lab | Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates |
| FR2875807B1 (fr) * | 2004-09-30 | 2006-11-17 | Servier Lab | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
-
2004
- 2004-09-30 FR FR0410335A patent/FR2875807B1/fr not_active Expired - Fee Related
-
2005
- 2005-05-24 PE PE2005000574A patent/PE20060364A1/es not_active Application Discontinuation
- 2005-05-26 MA MA28300A patent/MA27815A1/fr unknown
- 2005-05-27 GT GT200500130A patent/GT200500130A/es unknown
- 2005-05-30 CA CA002508824A patent/CA2508824C/fr not_active Expired - Fee Related
- 2005-05-31 AP AP2005003323A patent/AP1930A/xx active
- 2005-05-31 US US11/140,822 patent/US7459568B2/en not_active Expired - Fee Related
- 2005-06-02 OA OA1200500169A patent/OA13013A/fr unknown
- 2005-06-14 AR ARP050102423A patent/AR049395A1/es not_active Application Discontinuation
- 2005-06-15 SA SA05260168A patent/SA05260168B1/ar unknown
- 2005-06-15 CR CR7876A patent/CR7876A/es not_active Application Discontinuation
- 2005-06-15 MX MXPA05006407A patent/MXPA05006407A/es active IP Right Grant
- 2005-06-16 IL IL169237A patent/IL169237A/en not_active IP Right Cessation
- 2005-06-16 EC EC2005005859A patent/ECSP055859A/es unknown
- 2005-06-16 CO CO05058754A patent/CO5710195A1/es not_active Application Discontinuation
- 2005-06-16 CN CNB2005100753929A patent/CN100391956C/zh not_active Expired - Fee Related
- 2005-06-17 SI SI200530490T patent/SI1642897T1/sl unknown
- 2005-06-17 JP JP2005177199A patent/JP2006104184A/ja active Pending
- 2005-06-17 SG SG200503938A patent/SG121035A1/en unknown
- 2005-06-17 UA UAA200505970A patent/UA80008C2/uk unknown
- 2005-06-17 PL PL05291297T patent/PL1642897T3/pl unknown
- 2005-06-17 DE DE602005010359T patent/DE602005010359D1/de not_active Expired - Lifetime
- 2005-06-17 TW TW094120331A patent/TWI367881B/zh not_active IP Right Cessation
- 2005-06-17 NZ NZ540802A patent/NZ540802A/en not_active IP Right Cessation
- 2005-06-17 RS RSP-2008/0506A patent/RS51110B/sr unknown
- 2005-06-17 AT AT05291297T patent/ATE411308T1/de active
- 2005-06-17 EP EP05291297A patent/EP1642897B9/fr not_active Revoked
- 2005-06-17 ES ES05291297T patent/ES2314593T3/es not_active Expired - Lifetime
- 2005-06-17 GE GEAP20058848A patent/GEP20074106B/en unknown
- 2005-06-17 AU AU2005202718A patent/AU2005202718B2/en not_active Ceased
- 2005-06-17 PT PT05291297T patent/PT1642897E/pt unknown
- 2005-06-17 DK DK05291297T patent/DK1642897T3/da active
- 2005-06-17 EA EA200500842A patent/EA008474B1/ru not_active IP Right Cessation
- 2005-06-17 ZA ZA200504937A patent/ZA200504937B/en unknown
- 2005-06-17 EP EP08007270A patent/EP1944302A1/fr not_active Withdrawn
- 2005-06-17 NO NO20052998A patent/NO333948B1/no not_active IP Right Cessation
- 2005-06-17 WO PCT/FR2005/001515 patent/WO2006035122A1/fr not_active Ceased
- 2005-06-17 BR BRPI0502228-2A patent/BRPI0502228A/pt not_active IP Right Cessation
- 2005-07-01 PA PA20058638201A patent/PA8638201A1/es unknown
- 2005-07-08 KR KR1020050061542A patent/KR100816590B1/ko not_active Expired - Fee Related
-
2008
- 2008-08-12 US US12/228,381 patent/US7745482B2/en not_active Expired - Fee Related
- 2008-11-19 CY CY20081101327T patent/CY1108797T1/el unknown
- 2008-12-16 HR HR20080652T patent/HRP20080652T3/xx unknown
-
2010
- 2010-01-07 JP JP2010001847A patent/JP2010132669A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS51110B (sr) | Alfa kristalni oblik stroncijum ranelata, postupak njegove izrade i farmaceutske smeše koje ga sadrže | |
| CN101573368B (zh) | 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物 | |
| RS50598B (sr) | Kristalni oblik gama ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže | |
| RS50600B (sr) | Kristalni oblik gama - d ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže | |
| EP1650205A1 (en) | Cyclohexanecarboxylic acid compound | |
| GB1604674A (en) | Aminoalkyl-benzene derivatives | |
| JP3990399B2 (ja) | β２−受容体興奮作用を有する新規フェニルエタノールアミン類化合物及びそれらの製造方法 | |
| Singh et al. | Dithiocarbamate-based novel anti-histaminic agents: synthesis, characterization, crystal structure and thermal study | |
| CZ294401B6 (cs) | Morfinové a diamorfinové soli anionických nenarkotických analgetik typu substituovaných karboxylových kyselin, způsob jejich výroby, jejich použití a farmaceutické preparáty tyto soli obsahující | |
| JPS5989671A (ja) | ２，５−ピペラジンジオン誘導体 | |
| KR840000763B1 (ko) | 2-아미노-3-벤조일-페닐아세트아미드의 제조방법 | |
| CA2403264A1 (en) | Chiral fluoroquinolizinone arginine salt forms | |
| JPH0153266B2 (sr) | ||
| EP0552881A1 (en) | Anticancer benzaldehyde compounds | |
| KR840000605B1 (ko) | 2-아미노-3-(알킬티오벤조일)-페닐아세트산유도체의 제조방법 | |
| JP3182685B2 (ja) | 水和物結晶及びその製造方法 | |
| JPH02167272A (ja) | エタンスルホンアミド誘導体 | |
| HK1086260B (en) | Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it | |
| EP1509519B1 (en) | Crystalline fluoroquinolone arginine salt form | |
| KR820001615B1 (ko) | N-펜에틸 아세트아미드 화합물의 제조방법 | |
| CN102796073A (zh) | 制备(R)α-硫辛酸盐的方法、其制剂以及在含有该盐的片剂形式的药物组合物中的用途 | |
| JPS60202818A (ja) | 抗潰瘍剤 |